Volume 96, special issue 4, décembre 2009

Éditorial

Les mutations Kras et le traitement ciblé dans les carcinomes bronchiques non à petites cellules et les cancers colorectaux (p.3-4)
C Massard, T André

Synthèse

Mouse models of K-ras-initiated oncogenesis (p.5-14)
C Barrière, F El Marjou, D Louvard, S Robine

Technical considerations for KRAS testing in colorectal cancer. The pathologist’s point of view (p.15-22)
F Bibeau, H Frugier, A Denouel, J-C Sabourin, F Boissiere-Michot

Pronostic role of KRAS mutation in colorectal cancer (p.23-30)
F Di Fiore, P Michel

Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients (p.31-40)
D Smith, C Bosacki, Y Merrouche

Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis (p.41-6)
E Assenat, M Ychou

Technical considerations for KRAS testing in colorectal cancer. The biologist’s point of view (p.47-56)
H Blons, P Laurent-Puig

Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value (p.57-68)
D Planchard, Y Loriot, B Besse

Targeting KRAS pathway in NSCLC therapy (p.69-74)
S Le Moulec, Y Loriot, J-C Soria

KRAS status versus EGFR status in lung cancer therapy (p.75-83)
L Lacroix, B Besse, J-M Bidart, J Bosq

Cutaneous side effects of EGF receptor inhibitors (p.85-91)
D Nassar, B Soutou, S Aractingi